595 results on '"Kim, Hyo Jong"'
Search Results
2. Gut microbial and human genetic signatures of inflammatory bowel disease increase risk of comorbid mental disorders
3. Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets
4. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
5. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
6. Author Correction: Enterococcus faecium and Pediococcus acidilactici deteriorate Enterobacteriaceae-induced depression and colitis in mice
7. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
8. Patient-derived Enterococcus mundtii and its capsular polysaccharides cause depression through the downregulation of NF-κB-involved serotonin and BDNF expression
9. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
10. Enterococcus faecium and Pediococcus acidilactici deteriorate Enterobacteriaceae-induced depression and colitis in mice
11. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
12. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
13. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
14. Long‐term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow‐up in the SELECTION open‐label long‐term extension study.
15. MP40-16 DO CHANGES IN METABOLIC HEALTH AND OBESITY AFFECT THE INCIDENCE OF UROLITHIASIS?; A NATIONALLY REPRESENTATIVE COHORT STUDY
16. MP28-06 MID-TERM FOLLOW UP AFTER MODIFIED GRID INCISION AND SEALING WITH COLLAGEN FLEECE FOR TREATMENT OF PEYRONIE’S DISEASE
17. MP11-08 HUMAN PAPILLOMAVIRUS (HPV) PREVALENCE AND GENOTYPE DISTRIBUTION AMONG FEMALES IN SOUTH KOREA: IMPLICATIONS FOR VACCINATION STRATEGIES
18. Reliability and Validity Analyses of the Practical Assessment of Dysphagia Test in Stroke
19. Histopathological characteristics of progressive multifocal leukoencephalopathy in a patient with acquired immune deficiency syndrome (AIDS)
20. Transplantation of fecal microbiota from patients with inflammatory bowel disease and depression alters immune response and behavior in recipient mice
21. Dynamic Changes in the Gut Microbiota Composition during Adalimumab Therapy in Patients with Ulcerative Colitis: Implications for Treatment Response Prediction and Therapeutic Targets
22. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
23. Ultrasound-guided placement of Midline catheters performed by Neurosurgery resident as a substitute for conventional central venous catheter placement in Neurosurgical Intensive Care Unit patients
24. Effectiveness of antidepressant repetitive transcranial magnetic stimulation in a patient with refractory psychogenic dysphagia: A case report and review of literature
25. Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease—More thought is needed—Authors' reply
26. Host Genetic and Gut Microbial Signatures in Familial Inflammatory Bowel Disease
27. Clinicopathological Characteristics of Autoimmune-Like Hepatitis Induced by COVID-19 mRNA Vaccine (Pfizer-BioNTech, BNT162b2): A Case Report and Literature Review
28. Nationwide Trends in Osteoporosis in Koreans With Disabilities From 2008 to 2017
29. Su1707 EXPOSURE TO ANTI-TNFα AGENT INCREASES THE DEVELOPMENT OF AUTOIMMUNE DISEASE IN INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED CASE-CONTROL STUDY
30. Supplementary Figure 3 from Epigenetic Alteration of PRKCDBP in Colorectal Cancers and Its Implication in Tumor Cell Resistance to TNFα-Induced Apoptosis
31. Supplementary Figure 5 from Epigenetic Alteration of PRKCDBP in Colorectal Cancers and Its Implication in Tumor Cell Resistance to TNFα-Induced Apoptosis
32. Supplementary Figure 1 from Epigenetic Alteration of PRKCDBP in Colorectal Cancers and Its Implication in Tumor Cell Resistance to TNFα-Induced Apoptosis
33. Supplementary Figure Legends 1-6 from Epigenetic Alteration of PRKCDBP in Colorectal Cancers and Its Implication in Tumor Cell Resistance to TNFα-Induced Apoptosis
34. Supplementary Figure 4 from Epigenetic Alteration of PRKCDBP in Colorectal Cancers and Its Implication in Tumor Cell Resistance to TNFα-Induced Apoptosis
35. Supplementary Figure 6 from Epigenetic Alteration of PRKCDBP in Colorectal Cancers and Its Implication in Tumor Cell Resistance to TNFα-Induced Apoptosis
36. Supplementary Figure 2 from Epigenetic Alteration of PRKCDBP in Colorectal Cancers and Its Implication in Tumor Cell Resistance to TNFα-Induced Apoptosis
37. Supplementary Figure 4 from Caveolin-1 Increases Aerobic Glycolysis in Colorectal Cancers by Stimulating HMGA1-Mediated GLUT3 Transcription
38. Supplementary Figure Legends 1-6 from Caveolin-1 Increases Aerobic Glycolysis in Colorectal Cancers by Stimulating HMGA1-Mediated GLUT3 Transcription
39. Data from Caveolin-1 Increases Aerobic Glycolysis in Colorectal Cancers by Stimulating HMGA1-Mediated GLUT3 Transcription
40. Supplementary Figure 2 from Caveolin-1 Increases Aerobic Glycolysis in Colorectal Cancers by Stimulating HMGA1-Mediated GLUT3 Transcription
41. Supplementary Figure 3 from Caveolin-1 Increases Aerobic Glycolysis in Colorectal Cancers by Stimulating HMGA1-Mediated GLUT3 Transcription
42. Supplementary Figure 6 from Caveolin-1 Increases Aerobic Glycolysis in Colorectal Cancers by Stimulating HMGA1-Mediated GLUT3 Transcription
43. Supplementary Figure 1 from Caveolin-1 Increases Aerobic Glycolysis in Colorectal Cancers by Stimulating HMGA1-Mediated GLUT3 Transcription
44. Supplementary Figure 5 from Caveolin-1 Increases Aerobic Glycolysis in Colorectal Cancers by Stimulating HMGA1-Mediated GLUT3 Transcription
45. The effectiveness of low-dose and high-dose tranexamic acid in posterior lumbar interbody fusion: a double-blinded, placebo-controlled randomized study
46. sj-docx-1-tag-10.1177_17562848231168199 – Supplemental material for Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis
47. sj-docx-2-tag-10.1177_17562848231168199 – Supplemental material for Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis
48. Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis
49. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine
50. XAF1 forms a positive feedback loop with IRF-1 to drive apoptotic stress response and suppress tumorigenesis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.